Top-Rated StocksTop-RatedNASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $86.82 +0.34 (+0.39%) As of 05/26/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$85.43▼$89.2350-Day Range$77.76▼$95.7652-Week Range$16.64▼$96.50Volume377,714 shsAverage Volume464,495 shsMarket Capitalization$4.75 billionP/E RatioN/ADividend YieldN/APrice Target$117.82Consensus RatingBuy Company Overview Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 593rd out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $117.82, representing about 35.7% upside from its current price of $86.82.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -21.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -21.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.36% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 14.14, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 0.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Dianthus Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for DNTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,564,008.00 in company stock.Percentage Held by Insiders3.02% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesDianthus Therapeutics to Participate in Two Investor ConferencesMay 26 at 4:01 PM | globenewswire.comHead-To-Head Analysis: Dyadic International (NASDAQ:DYAI) and Dianthus Therapeutics (NASDAQ:DNTH)May 24 at 4:06 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic DiseasesMay 19, 2026 | globenewswire.comAssessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital RaiseMay 19, 2026 | finance.yahoo.comWhy This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyMay 17, 2026 | fool.comAnalysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Dianthus Therapeutics (DNTH)May 13, 2026 | theglobeandmail.comLBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisMay 5, 2026 | globenewswire.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $41.21 on January 1st, 2026. Since then, DNTH stock has increased by 110.7% and is now trading at $86.82. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company earned $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative trailing twelve-month return on equity of 27.30%. When did Dianthus Therapeutics IPO? Dianthus Therapeutics (DNTH) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Dianthus Therapeutics' major shareholders? Top institutional shareholders of Dianthus Therapeutics include Octagon Capital Advisors LP (3.56%), Jennison Associates LLC (0.89%), Spruce Street Capital LP (0.68%) and Dimensional Fund Advisors LP (0.60%). Insiders that own company stock include Fairmount Funds Management Llc, Ryan Savitz, Simrat Randhawa, Marino Garcia and Edward Carr. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/05/2026Today5/27/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DNTH's financial health is in the Green zone, according to TradeSmith. DNTH has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$117.82 High Price Target$145.00 Low Price Target$98.00 Potential Upside/Downside+35.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.34 million Net Margins-12,998.50% Pretax Margin-12,998.50% Return on Equity-27.30% Return on Assets-25.91% Debt Debt-to-Equity RatioN/A Current Ratio29.25 Quick Ratio29.25 Sales & Book Value Annual Sales$1.34 million Price / Sales3,552.47 Cash FlowN/A Price / Cash FlowN/A Book Value$21.98 per share Price / Book3.95Miscellaneous Outstanding Shares54,666,000Free Float53,015,000Market Cap$4.75 billion OptionableOptionable Beta1.18 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:DNTH) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
